J.P. Morgan Maintained a Hold Rating on LifeStance Health (LFST)

LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the 11 Best All-Time Low Stocks to Buy According to AnalystsOn May 28, Lisa Gill from J.P. Morgan maintained a Hold rating on LifeStance Health Group, Inc. (NASDAQ:LFST) with a price target of $8.

The company is set to release its fiscal second quarter results on August 7, 2025. Gill maintained a cautious rating despite the company’s strong performance in Q1 2025. LifeStance Health Group, Inc. (NASDAQ:LFST) delivered $333 million in revenue during the first quarter, reflecting an 11% increase and ahead of expectations by $77,190. Management noted that the number of clinicians grew 10% to 7,535, adding 152 new clinicians in the quarter, whereas the patient visit volumes also increased 10% to 2.1 million.

J.P. Morgan Maintained a Hold Rating on LifeStance Health (LFST)

A close-up of a healthcare professional studying a computer screen with data while consulting with a patient.

For full-year 2025, LifeStance Health Group, Inc. (NASDAQ:LFST) expects revenue between $1.40 billion and $1.44 billion. The company forecasts a center margin of $440 million to $464 million and adjusted EBITDA of $130 million to $150 million.

LifeStance Health Group, Inc. (NASDAQ:LFST) provides virtual and in-person outpatient mental healthcare for people of all ages. Their services include psychiatric evaluations, therapy, and testing for various mental health conditions like anxiety and depression.

While we acknowledge the potential of LFST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LFST and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.